The bionic eye – behind the headlines

BY ROD MCNEIL

Multiple visual prosthetic projects and other vision regeneration initiatives being tested in preclinical and clinical development worldwide illustrate continuing progress and opportunities in addressing profound blindness from hereditary retinal diseases and other causes (Table 1).

Three implantable bionic vision systems are currently clinically approved by regulatory authorities in Europe for restoration of basic visual function in individuals blinded by outer retinal degeneration: Argus II retinal prosthesis system (Second Sight Medical Products), subretinal visual implant Alpha AMS (Retina Implant AG), and Intelligent Retinal Implant System (IRIS) V2 bionic vision system (Pixium Vision). Below, the author reviews currently available options and presents an insider’s update direct from recent conversations with movers and shakers driving these technologies.

**Argus II retinal prosthesis system**

The Argus II retinal prosthesis system secured regulatory approval in the European Economic

### Table 1: Treatment of profound or severe blindness: examples of vision restoration and regeneration initiatives.

<table>
<thead>
<tr>
<th><strong>Retinal prostheses</strong></th>
<th>Providing basic visual ability to a blind patient via implanting a device in the eye to stimulate remaining retina. Developers include American company Second Sight Medical Products, Retina Implant AG, Pixium Vision of France, Israel-based NanoRetina, Inc. and several academic centres in Australia, the United States, and Europe.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Transplantation</strong></td>
<td>Whole eye transplantation, offering the opportunity to provide viable retinal ganglion cells and entire optical system to recipients with vision loss and irreversible eye injury. Transplanting retinal tissue to stimulate remaining retina cells.</td>
</tr>
<tr>
<td><strong>Stem cells</strong></td>
<td>Involves implanting immature retinal support cells aimed at slowing retinal degeneration.</td>
</tr>
<tr>
<td><strong>Genetics and gene therapy</strong></td>
<td>Spark Therapeutics’ product candidate voretigene neparvovec (formerly referred to as SPK-RPE65) has received breakthrough therapy and orphan product designations. The company has reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of RPE65-mediated inherited disease.</td>
</tr>
<tr>
<td><strong>Optogenetics therapy</strong></td>
<td>RetroSense Therapeutics is testing optogenetics therapy for the treatment of retinitis pigmentosa – blind patients are injected with a virus containing DNA from a light-sensitive algae.</td>
</tr>
<tr>
<td><strong>Implantable telescope</strong></td>
<td>VisionCare Ophthalmic Technologies, Inc. offers a US FDA-approved implantable miniature telescope for AMD, a magnifying device that is implanted in the eye. The VisionCare telescope is approved for use in patients with severe to profound vision impairment (BCVA of 20/160 to 20/800) due to dry AMD.</td>
</tr>
<tr>
<td><strong>BrainPort® V100</strong></td>
<td>Wicab, Inc. has developed the BrainPort® V100, which features a tongue array containing 400 electrodes and connected to glasses via a flexible cable. Approved by the US FDA in 2015, the system includes a video camera mounted on a pair of sunglasses, a handheld controller and tongue array. The BrainPort® V100 can be used regardless of the cause or duration of blindness, and does not require an intact optic nerve in order to function. Individuals blinded by congenital and acquired causes may use the BrainPort® V100.</td>
</tr>
</tbody>
</table>
Five-year safety and performance results

Argus II clinical trial

Five-year outcome results from

- individually programmable
- MRI compatible
- a relatively large field of view (20 degrees)
- surgical implantation in three to four hours using standard vitreoretinal techniques (median duration of the Argus II surgical implant procedure is less than three hours)
- a relatively large field of view (20 degrees)
- MRI compatible
- individually programmable electrodes on the prosthesis, permitting further optimisation of the device after implantation.

Key technical and other features include:

- demonstrated lifetime over eight and a half years
- demonstrated stable clinical benefit over six years
- surgical implantation in three to four hours using standard vitreoretinal techniques (median duration of the Argus II surgical implant procedure is less than three hours)
- a relatively large field of view (20 degrees)
- MRI compatible
- individually programmable electrodes on the prosthesis, permitting further optimisation of the device after implantation.

Five-year outcome results from Argus II clinical trial

Five-year safety and performance results from the international Argus II clinical trial, involving 30 enrolled participants in 10 centres in the United States and Europe from both pre- and post-market approval implantations, confirm the long-term safety profile and benefit of the Argus II system for profoundly blind retinitis pigmentosa patients [1]:

- **Safety.** At five years after implantation, 60% of patients (18/30) had experienced no device- or surgery-related serious adverse event, and there were no lost eyes (enucleated). The most common serious adverse events occurring up to five years after implantation were conjunctival erosion (13.3%), hypotony (13.3%), conjunctival dehiscence (10%) and presumed endophthalmitis (10%, all three cases occurring within two months after implantation and within the first year of the overall study start). There were two Argus II implant device failures and three complete or partial explantations, and 24 devices remained implanted and functioning.

- **Efficacy.** Results show that patients performed significantly better with the Argus II on than off on all visual function tests (square localisation, shape and object recognition, and reading of letters and short unrehearsed words have been shown. There is nonetheless wide variability in the functional outcomes amongst the patients [2]. The Argus II Study Group concluded that long-term outcome data demonstrate that the Argus II system has an acceptable safety profile, and may allow for durable, stable and reliable restoration of some basic visual function for patients with retinitis pigmentosa who have bare light perception or less.

**Durable benefit observed out to 10 years following implantation**

Grégoire Cosendai, European Vice President of Second Sight, commented: “These long-term follow-up data confirm that the vast majority of patients implanted with the Argus II system experience an objective improvement in visual function that remains stable through five years. A similarly durable benefit has been observed out to 10 years after implantation with the original Argus I system.

“We have reported clear daily life benefits: the way the patients integrate visual function benefit in their daily life. We can demonstrate, for example, how patients can attempt to safely cross the street without the system – they are successful 18% of the time with the system off and 65% of the time with the system on [3]. This is a real life change in a task that is extremely difficult to achieve if you’re blind, but is demonstrably and significantly more successful with the Argus II.”

Mr Cosendai continued: “Since 2011 we have introduced 15 upgrades to the Argus II system, and in early 2017 we plan to introduce enhanced external hardware,
Retina Implant AG. Oxford University since 2014. To date, CE marked in 2013. The latest Alpha generation of the Alpha IMS device marketing approval for its new wireless Retina Implant AG received CE IMS/AMS (Retina Implant AG) Subretinal visual implant Alpha optic nerve disease and other causes. profound blindness from eye trauma, vision with cortical stimulation to treat prosthesis system, designed to restore development. The company is also developing a visual cortical prosthesis named Orion I visual prosthetic system, designed to restore vision with cortical stimulation to treat profound blindness from eye trauma, optic nerve disease and other causes.

Subretinal visual implant Alpha IMS/AMS (Retina Implant AG) Retina Implant AG received CE marketing approval for its new wireless subretinal Alpha AMS neuroprosthetic implant in March 2016, the next generation of the Alpha IMS device CE marked in 2013. The latest Alpha AMS technology has been evaluated in clinical trials in Germany and at Oxford University since 2014. To date, 52 patients have been implanted with a Retina Implant AG subretinal visual prosthesis, 15 receiving the latest Alpha AMS model.

The Retina Implant Alpha AMS system consists of a subretinal microchip (multiphotodiode-array) on a polyimide foil, both placed subretinally, and a power supply and signal control cable, ending in a receiver coil, housed together with electronic circuits in a small box placed subdermally at the temple and retroauricular region behind the ear. The Alpha AMS light-sensitive 1600 photodiode-array is positioned in the layer of the degenerated photoreceptors, and stimulates the bipolar cell layer at the retinal input, using the processing power of the neuronal network of the inner retina. The transchoroidal implantation procedure is more challenging than the epiretinal insertion approach for Argus II, entailing a two-part surgical procedure with a typical duration of between five and eight hours. An interim clinical trial report published in 2015 provides proof of principle that the subretinal Alpha IMS visual prosthesis can restore reliably measurable visual function and potentially useful vision in low-vision or very low-vision range in selected patients with end-stage hereditary retinal degenerations [4]. Findings during up to 12 months’ follow-up of 29 blind patients with outer retinal degeneration implanted with the Alpha IMS device include:

- 72% of patients showed a significant improvement in daily living tasks, recognition and mobility (primary efficacy endpoints)
- improvement in light detection, with more than 86% able to detect light, including identification of specific light sources
- thirteen participants (45%) reported useful new daily life experiences with the implant, being able to see shapes and / or details of objects in grey scales
- transchoroidal implantation surgery was found to be a safe procedure
- there were two serious adverse events reported, an increase in IOP up to 46mmHg and retinal detachment immediately following device explantation, both treated successfully and without long-term sequelae.

Improvement of visual function from blindness to a low-vision or very-low vision range can provide considerable benefit for participants who become blind from progressive degeneration of the retina, added study authors. Most participants in this international multicentre clinical trial were able to localise objects with a good contrast within their own environment, although technical failures of the implants limited the number of participants who performed evaluation tests in later follow-up visits.

**Benefit in daily life experience for around half of implanted patients**

Professor Eberhart Zrenner, co-founder of Retina Implant AG and co-author of the 2015 interim clinical report, commented: “We cannot predict which patients will benefit most in terms of visual perception after implantation. Clinical experience shows that approximately one quarter do not benefit in daily life, due to advanced retinal degeneration, while another quarter experience improved light perception but cannot recognise shapes or details. Around 50% of implanted patients experience useful new daily life experiences with the implant, with one quarter being able to recognise and read letters.

“...The best result of measured grating visual acuity is 20/346. The time necessary for relearning vision is relatively short, with patients often able to localise objects or details within a few weeks after implantation.”

Prof Zrenner added: “The main challenges of currently available retinal implants are technical biostability and the limited spatial resolution. Future technology developments in visual prostheses will focus on increasing the visual field (e.g. two chips instead of one), miniaturisation of electronic components, as well as enhanced brightness, image processing capabilities and improved patient handling.”

**IRIS II bionic vision system and PRIMA, photovoltaic retinal prosthesis**

Paris-based Pixium Vision obtained CE mark certification of its IRIS® II bionic vision system in July 2016. The ‘Intelligent Retinal Implant System’ V2 is a 150-electrode epiretinal implant equipped with a bio-inspired camera designed for people with vision loss from outer retinal degeneration. IRIS II features an explantable design. The
Electrode array is secured on the retinal surface by a patented support system intended to allow for explantation so as to facilitate future next-generation replacements or upgrades to hardware and / or software. Another distinctive feature is a bio-inspired camera intended to mimic the functioning of the human eye by continuously capturing changes in the visual scene with its time independent pixels.

Khalid Ishaque, CEO of Pixium Vision, explained: “The median implant surgery time for IRIS II is approximately two to two and a half hours, which compares favourably with other CE-mark approved bionic prosthetic vision systems. We have also focused on increasing the number of electrodes to 150 from the earlier 49-electrode model, to increase the likelihood of better visual outcomes overall, with better resolution. The explantable design offers patients the possibility of benefiting from future system or technology enhancements through modular upgrades, via hardware and / or software.”

The IRIS II clinical trial, underway across multiple European centres, is an open label, non-randomised prospective study designed to assess longer-term performance of the IRIS II bionic vision system as a treatment to compensate for blindness in patients (n=10) with retinal dystrophy (retinitis pigmentosa, cone-rod dystrophy, or choroideremia). Efficacy is measured using functional vision and visual function tests before and after implantation as well as with the system on and system off, with follow-up through to 36 months.

“Preliminary interim data evaluating functional vision and visual acuity following implantation of IRIS II suggest outcome benefits that are similar to, and in some instances better than, those published with Argus II through 18 months’ follow-up,” noted Khalid Ishaque. “Patient experience emphasises the benefit of additional orientation guidance indication provided by the bionic vision implant, with patients reporting that they feel empowered to be more independent and to navigate with greater confidence.”

**Can we do better? Photovoltaic technology advances towards clinical testing**

Pixium Vision is developing a second retinal bionic vision system named PRIMA in partnership with Daniel Palanker and his team at Stanford University. This is a miniature, wireless subretinal photovoltaic prosthetic vision restoration in patients with dry (AMD). Currently in preclinical development, Pixium Vision will launch clinical trials evaluating PRIMA in Europe later in 2016.

The photovoltaic subretinal prosthetic vision system directly converts light into pulsed electric current in each pixel, stimulating nearby inner retinal neurons. Vision information is projected onto the retina by video goggles using pulsed near-infrared light. Researchers at Stanford developed the photovoltaic arrays with pixels down to 70µm in width, and tested prosthetic vision ex-vivo and in-vivo [5]. Tests in animals blinded by retinal degeneration showed the implant restores visual acuity to an equivalent of 20/250, five times greater than the visual acuity of up to about 20/1200 observed with existing retinal prostheses in humans, according to researchers. The modular design of these wireless arrays allows scalability to thousands of pixels, and combined with ease of implantation with an implant surgery time goal of sub one hour, offers a promising approach to restoration of sight in patients blinded by retinal degenerative diseases.

“The holy grail of prosthetic vision is face recognition, a breakthrough that we hope may well be attainable with wireless subretinal photovoltaic technology,” added Khalid Ishaque.

**Patient expectations: continuing access to evolving technology and vision rehabilitation support**

Depending on the stage of retinal degeneration, available therapy options may range from participating in gene or cell therapy trials and, in the case of advanced or end-stage outer retinal degeneration, retinal prostheses.

Factors to consider when selecting an appropriate bionic eye implant for an individual profoundly blind due to retinitis pigmentosa or other hereditary retinal disease include complexity and duration of implantation procedure, long-term stability of vision benefit after implantation, short- and long-term complication rates and functional performance and reliability as a chronically implanted device. Patients expect upgradeability as technology evolves, together with provision of vision rehabilitation support from artificial vision specialists or multidisciplinary centres.
References

• Retinal implants can be used effectively to improve visual perception in patients profoundly blind due to hereditary degenerative retinal diseases.
• Long-term outcome data demonstrate that the Argus II system may allow for stable and reliable restoration of some basic visual function for patients with retinitis pigmentosa who have bare light perception or less.
• Ongoing clinical trials are evaluating outcome benefits of retinal prostheses for individuals with severe or profound vision loss due to dry AMD.
• Photovoltaic retinal prosthesis technology, combined with ease of implantation, offers a promising approach to restoration of sight in patients with retinal injury or degeneration.
• Visual cortical prostheses are being developed to restore vision with cortical stimulation to treat profound blindness from eye trauma, optic nerve disease and other causes.

Figure 6: PRIMA, a subretinal miniaturised wireless implant platform currently in preclinical studies (courtesy of Pixium Vision).